State of the Art-A Journey through the World of Antithrombotic Therapy

Alexander G. G. Turpie

doi:10.1055/s-2002-34080

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2002; 28(s3): 003-012
DOI: 10.1055/s-2002-34080

State of the Art-A Journey through the World of Antithrombotic Therapy

Alexander G.G. Turpie

HHS General Hospital, McMaster Clinic, Hamilton, Ontario, Canada

Abstract

ABSTRACT

The introduction of low-molecular-weight heparins (LMWHs) has contributed to major improvements in the management of venous thromboembolism (VTE). The LMWHs have been shown to be as effective as, and safer than, unfractionated heparin (UFH) in the prevention and treatment of VTE, and their use is included as a grade 1A recommendation in the Sixth American College of Chest Physicians Guidelines. Important practical disadvantages of treatment with UFH are the need for extended hospital stays and frequent monitoring of coagulation levels. In comparison, LMWHs offer convenient and cost-effective prophylaxis and treatment of VTE on an outpatient basis. The LMWHs have also had a major impact on the management of arterial thromboembolism. In patients with acute coronary syndromes (unstable angina and non-ST-segment elevation myocardial infarction), enoxaparin has demonstrated sustained clinical improvements in major ischemic outcomes compared with UFH. Antiplatelet agents have also contributed significantly to the development of effective antithrombotic therapy. Aspirin is the best known antiplatelet agent and has heretofore been the mainstay of antiplatelet therapy in unstable angina. New data indicate that combination therapy with aspirin and a novel thienopyridine, clopidogrel, may further improve outcomes in this indication.

KEYWORDS

Venous thromboembolism - antithrombotic therapy - low-molecular-weight heparin - acute coronary syndromes - antiplatelet agents

Full Text

References

REFERENCES

1 Anderson Jr A F, Brownell Wheeler H, Goldberg R J. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med . 1991; 151 933-938
2 Geerts W H, Heit J A, Clagett G P. Prevention of venous thromboembolism. Chest . 2001; 119(Suppl 1) 132S-175S
3 Leizorovicz A, Haugh M C, Chapuis F R, Samama M M, Boissel J P. Low molecular weight heparin in the prevention of perioperative thrombosis. Br Med J . 1992; 305 913-920
4 Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol . 1997; 11 489-509
5 Green D, Hirsh J, Heit J. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev . 1994; 46 89-109
6 Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis?. Thromb Res . 2000; 100 V113-V120
7 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med . 1995; 332 1330-1335
8 Wiggins B S, Wittowsky A K, Nappi J M. Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes. Pharmacotherapy . 2001; 21 320-337
9 Turpie A G, Levine M N, Hirsh J. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med . 1986; 315 925-929
10 Nurmohamed M T, Rosendaal F R, Büller H R. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet . 1992; 340 152-156
11 Cohen A T, Khushal A. Extended thromboprophylaxis following lower limb arthroplasty: what do the clinical trials mean?. Haemostasis . 2000; 30(Suppl 2) 88-94
12 The Sixth ACCP Guidelines for Antithrombotic Therapy. Chest 2001 119(Suppl 1): 1S-370S
13 Bouthier J. The venous thrombotic risk in nonsurgical patients. Drugs . 1996; 52(Suppl 7) 16-29
14 Bergmann J F, Elkharrat D. Prevention of venous thromboembolic risk in non-surgical patients. Haemostasis . 1996; 26(Suppl 2) 16-23
15 Sandler D A, Martin J F. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. J R Soc Med . 1989; 82 203-205
16 Samama M M, Cohen A T, Darmon J Y. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med . 1999; 341 793-800
17 Brandjes D P, Heijboer H, Büller H R. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med . 1992; 327 1485-1489
18 Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet . 1986; 2 1293-1296
19 Hull R D, Raskob G E, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med . 1990; 322 1260-1264
20 Lensing A W, Prins M H, Davidson B L, Hirsh L. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med . 1995; 155 601-607
21 van der Heijden F J, Prins M H, Büller H R. Low-molecular-weight heparins: are they interchangeable?. Haemostasis . 2000; 30(Suppl 2) 148-157
22 Hyers T M, Agnelli G, Hull R D. Antithrombotic therapy for venous thromboembolic disease. Chest . 2001; 119(Suppl 1) 176S-193S
23 Levine M N, Gent M, Hirsh J. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med . 1996; 334 677-681
24 Koopman M M, Prandoni P, Piovella F. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. The Tasman Study Group. N Engl J Med . 1996; 334 682-687
25 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med . 1997; 337 657-662
26 Hull R, Delmore T, Genton E. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med . 1979; 301 855-858
27 Hull R, Delmore T, Carter C. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med . 1982; 306 189-194
28 Hull R, Hirsh J, Jay R. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med . 1982; 307 1676-1681
29 Kearon C, Gent M, Hirsh J. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med . 1999; 340 901-907
30 Cohen M, Demers C, Gurfinkel E P. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events Study Group. N Engl J Med . 1997; 337 447-452
31 Antman E M, McCabe C H, Gurfinkel E P. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation . 1999; 100 1593-1601
32 Klein W, Buchwald A, Hillis S E. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation . 1997; 96 61-68
33 The FRAX.I.S Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S (FRAXiparine in Acute Ischaemic Syndrome). Eur Heart J . 1999; 20 1553-1562
34 Cohen M. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction. Semin Thromb Hemost . 1999; 25(Suppl 3) 113-121
35 Goodman S G, Cohen M, Bigonzi F. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol . 2000; 36 693-698
36 Bosanquet N, Fox K AA. Longer term economic benefits reflect improved clinical outcomes with enoxaparin versus unfractionated heparin in acute coronary syndromes: one-year data. Br J Cardiol . 2001; 8 36-37
37 Eikelboom J W, Anand S S, Malmberg K. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet . 2000; 355 1936-1942
38 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988 2: 349-360
39 Cairns J A, Gent M, Singer J. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med . 1985; 313 1369-1375
40 Yusuf S, Zhao F, Mehta S R. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med . 2001; 345 494-502